Focus Advisor Solutions LLC boosted its holdings in AbbVie Inc. (NYSE:ABBV – Free Report) by 62.8% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 64,299 shares of the company’s stock after buying an additional 24,814 shares during the quarter. Focus Advisor Solutions LLC’s holdings in AbbVie were worth $16,820,000 at the end of the most recent reporting period.
Several other institutional investors also recently modified their holdings of the stock. Financial Freedom LLC purchased a new stake in shares of AbbVie during the third quarter valued at $29,000. Burk Holdings LLC acquired a new position in shares of AbbVie in the 2nd quarter valued at $30,000. Marquette Asset Management LLC increased its stake in AbbVie by 52.2% in the 2nd quarter. Marquette Asset Management LLC now owns 140 shares of the company’s stock worth $35,000 after purchasing an additional 48 shares in the last quarter. IMG Wealth Management Inc. increased its stake in AbbVie by 3,060.0% in the 2nd quarter. IMG Wealth Management Inc. now owns 158 shares of the company’s stock worth $40,000 after purchasing an additional 153 shares in the last quarter. Finally, Principia Wealth Advisory LLC raised its holdings in AbbVie by 38.9% during the 2nd quarter. Principia Wealth Advisory LLC now owns 157 shares of the company’s stock worth $40,000 after buying an additional 44 shares during the period. Institutional investors own 70.23% of the company’s stock.
AbbVie Trading Down 2.4%
NYSE:ABBV opened at $285.92 on Thursday. The business’s fifty day moving average price is $277.84 and its 200 day moving average price is $241.96. The firm has a market capitalization of $505.39 billion, a price-to-earnings ratio of 49.21, a PEG ratio of 1.33 and a beta of 0.20. AbbVie Inc. has a 1-year low of $190.75 and a 1-year high of $302.93.
AbbVie (NYSE:ABBV – Get Free Report) last announced its quarterly earnings data on Friday, October 30th. The company reported $3.82 EPS for the quarter, topping analysts’ consensus estimates of $3.73 by $0.09. AbbVie had a negative return on equity of 450.55% and a net margin of 15.67%. The firm had revenue of $17.40 billion during the quarter, compared to analyst estimates of $17.32 billion. During the same period last year, the company posted $1.86 EPS. The business’s quarterly revenue was up 10.3% compared to the same quarter last year. Equities analysts forecast that AbbVie Inc. will post 13.98 earnings per share for the current year.
AbbVie Increases Dividend
The business also recently declared a quarterly dividend, which will be paid on Tuesday, February 16th. Investors of record on Friday, January 15th will be issued a dividend of $1.82 per share. This is an increase from AbbVie’s previous quarterly dividend of $1.73. This represents a $7.28 annualized dividend and a dividend yield of 2.5%. The ex-dividend date is Friday, January 15th. AbbVie’s dividend payout ratio is 119.10%.
Insider Buying and Selling
In other AbbVie news, EVP Jeffrey Stewart sold 40,619 shares of AbbVie stock in a transaction on Monday, November 9th. The shares were sold at an average price of $293.60, for a total transaction of $11,925,738.40. Following the completion of the sale, the executive vice president owned 83,171 shares of the company’s stock, valued at $24,419,005.60. This trade represents a 32.81% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 0.06% of the company’s stock.
Key Stories Impacting AbbVie
These are some of the ABBV stories that stood out recently:
- Positive Sentiment: Barclays raised its price target to $335 from $325 and maintained an Overweight rating, citing continued upside potential. AbbVie Is Up 27% in a Year. Barclays Sees Another 14%
- Positive Sentiment: AbbVie’s neuroscience franchise grew operational sales 19.5% in the third quarter, and the company lifted its 2026 sales outlook for the segment to $13 billion—evidence of momentum beyond its established medicines. How Did AbbVie’s Neuroscience Franchise Perform in Q3?
- Neutral Sentiment: Brokerages’ consensus price target was reported at $297.85. That is above the recent share price, but below Barclays’ new $335 target, reflecting differing views on the stock’s potential. AbbVie Stock Has Consensus Target Price of $297.85 According to Brokerages
Wall Street Analyst Weigh In
A number of analysts have commented on the stock. Barclays upped their price objective on shares of AbbVie from $325.00 to $335.00 and gave the company an “overweight” rating in a research note on Monday. Weiss Ratings raised shares of AbbVie from a “buy (b-)” rating to a “buy (b)” rating in a research report on Thursday, October 8th. Piper Sandler set a $349.00 target price on shares of AbbVie and gave the stock an “overweight” rating in a research report on Wednesday. Oppenheimer boosted their price target on shares of AbbVie from $244.00 to $258.00 and gave the company a “neutral” rating in a report on Monday, August 3rd. Finally, Rothschild & Co Redburn upped their price target on shares of AbbVie from $284.00 to $285.00 and gave the company a “buy” rating in a research report on Tuesday, August 4th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $299.62.
Get Our Latest Analysis on AbbVie
About AbbVie
AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for a range of serious health conditions. Its research and product portfolio spans immunology, oncology, neuroscience and other therapeutic areas. Key products include the immunology medicines Skyrizi and Rinvoq, cancer treatments such as Imbruvica and Venclexta, and neuroscience therapies including Botox and Vraylar. Through its Allergan acquisition, AbbVie also offers aesthetics products such as Botox Cosmetic and Juvéderm.
Recommended Stories
- Five stocks we like better than AbbVie
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
